Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – X-ray contrast imaging agent
Reexamination Certificate
2007-05-25
2010-02-09
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
X-ray contrast imaging agent
C424S009400
Reexamination Certificate
active
07658913
ABSTRACT:
The present invention provides compositions and methods to reduce renal damage caused by nephrotoxic drugs. The invention provides compositions comprising a substituted cyclodextrin, a nephrotoxic drug and a pharmaceutically acceptable carrier, where the cyclodextrin is present in an amount effective for substantially inhibiting the nephrotoxic effect of the drug.
REFERENCES:
patent: 4247535 (1981-01-01), Lewis et al.
patent: 4654325 (1987-03-01), Selenke
patent: 4727064 (1988-02-01), Pitha
patent: 4877778 (1989-10-01), Carpenter et al.
patent: 5134127 (1992-07-01), Stella et al.
patent: 5441944 (1995-08-01), Weisz et al.
patent: 5759573 (1998-06-01), Kim
patent: 6060597 (2000-05-01), Tobe et al.
patent: 6407079 (2002-06-01), Müller et al.
patent: 6730664 (2004-05-01), Muggetti et al.
patent: 6903100 (2005-06-01), Rowe
patent: 7026288 (2006-04-01), Judice et al.
patent: 2003/0008875 (2003-01-01), Rowe
patent: 2004/0048871 (2004-03-01), Rowe
patent: 2005/0032676 (2005-02-01), Judice et al.
patent: 2005/0234017 (2005-10-01), Zeldis
patent: 1020010084737 (2001-09-01), None
patent: WO8200251 (1982-02-01), None
patent: WO 03/053475 (2003-07-01), None
Miller, J.C. (2003) Minimizing Adverse Reactions to Contrast Agents in Radiology Rounds, vol. 1, issue 5.
Goodman and Gilman's The Pharmacological Basis of Therapeutics. editors Joel G. Hardman and lee E. Limbird, published by The McGraw-Hill Companies, Inc., 2001, p. 54-56.
Hewlett, T. (2004) Nephrotoxic drugs. Canadian Family Physician, vol. 50, p. 709-711.
Uekama, K. (2004) Design and Evaluation of Cyclodextrin-Based Drug Formulation. Chemical and Pharmaceutical Bulletin, vol. 52, No. 8, p. 900-915.
Sahani, D., Setty, B. (2005) Contrast Media: New Agents, New Concepts. Imaging Economics. Retrieved online from <http://www.imagingeconomics.com/issues/articles/2005-07—03.asp> on Sep. 21, 2009.
Widemann, B.C., et al.,Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol, 1997. 15(5): p. 2125-34.
Ackland, S.P. and R.L. Schilsky,High-dose methotrexate: a critical reappraisal. J Clin Oncol, 1987. 5(12): p. 2017-31.
Perazella, M.A.,Crystal-induced acute renal failure. Am J Med, 1999. 106(4): p. 459-65.
Schomagel, J.H. and J.G. McVie,The clinical pharmacology of methotrexate. Cancer Treat Rev, 1983. 10(1): p. 53-75.
Skarby, T., et al.,High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia(ALL). Cancer Chemother Pharmacol, 2003. 51(4): p. 311-20.
Challa, R., Ahuja, A., Khar, RK,Cyclodextrins in Drug Delivery: an updated review. AAPS PharmSciTech, 2005. 6(2): p. E329-E357.
Stella, V.J., et al.,Mechanisms of drug release from cyclodextrin complexes. Adv Drug Deliv Rev, 1999. 36(1): p. 3-16.
Schaschke, N., et al.,Beta-cyclodextrin/epoxysuccinyl peptide conjugates: a new drug targeting system for tumor cells. Bioorg Med Chem Lett, 2000. 10(7): p. 677-80.
Uekama, K., et al.,Protective effects of cyclodextrin sulphates against gentamicin-induced nephrotoxicity in the rat. J Pharm Pharmacol 1992. 45(8): p. 745-7.
Uekama, K.,Design and evaluation of cyclodextrin-based drug formulation. Chem Pharm Bull 2004. 52(8) p. 900-15.
Singh, U.V., et al.,Physicochemical and biological studies of inclusion complex of methotrexate with β-cyclodextrin. Pharm Sciences 1997. 3: p. 573-77.
Kikuchi et al., “Effect of Dextran Sulfate on Renal Accumulation of Gentamicin” Pharmaceutical Research, vol. 7, No. 6, 1990, pp. 644-647.
International Search Report for PCT Application No. PCT/US08/64489, dated Sep. 3, 2008.
Aime et al., “Contrast Agents for Magnetic Resonance Imaging: A Novel Route to Enhanced Relaxivities Based on the Interaction of Gd III Chelate with Poly-beta-cyclodextrins.” Chem. Eur. J. 1999, vol. 5, pp. 1253-1260; Abstract.
Ikeguchi et al. “Cisplatin Combined With Prostaglandin El Chemotherapy In Rat Peritoneal Carcinomatosis” Int. J. Cancer, 2000, vol. 88, pp. 474-478; Abstract.
Goon Scarlett
Jiang Shaojia Anna
Merchant & Gould
Verrow Pharmaceuticals, Inc.
LandOfFree
Compositions useful for reducing nephrotoxicity and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions useful for reducing nephrotoxicity and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions useful for reducing nephrotoxicity and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4199486